ZHIZHENG ZHANG^1,#, TAO LI^2,#, YUAN LI³, XI WANG⁴, HAO LIU⁵, XINYU SHEN⁵, ANN XU⁶, TIANSONG XIA^1,*, BO XU^7,*

Oncology Research, Vol.33, No.4, pp. 811-819, 2025, DOI:10.32604/or.2024.050505 - 19 March 2025

Abstract Background: Breast cancer is a prevalent malignant tumor affecting females, with treatment options including surgery, radiotherapy, chemotherapy, and endocrine therapy. Methods: This review synthesizes existing literature on breast cancer stem cells and their applications in breast cancer treatment. PubMed, Web of Science, and other relevant databases were systematically searched using keywords such as “breast cancer stem cells,” “immunotherapy,” “gene therapy,” and “cell therapy.” Studies published in English were included, and their findings were analyzed to provide insights into the characteristics and therapeutic potential of breast cancer stem cells. Results: Breast cancer stem cells exhibit unique properties More >

FEI CHU¹, KAI TONG¹, XIANG GU¹, MEI BAO¹, YANFEN CHEN¹, BIN WANG², YANHUA SHAO¹, LING WEI^1,*

Oncology Research, Vol.32, No.10, pp. 1661-1671, 2024, DOI:10.32604/or.2024.048287 - 18 September 2024

Abstract Glutamine is one of the most abundant non-essential amino acids in human plasma and plays a crucial role in many biological processes of the human body. Tumor cells take up a large amount of glutamine to meet their rapid proliferation requirements, which is supported by the upregulation of glutamine transporters. Targeted inhibition of glutamine transporters effectively inhibits cell growth and proliferation in tumors. Among all cancers, digestive system malignant tumors (DSMTs) have the highest incidence and mortality rates, and the current therapeutic strategies for DSMTs are mainly surgical resection and chemotherapy. Due to the relatively More > Graphic Abstract

LU SUN^1,2, HUAICHENG TAN¹, TING YU³, RUICHAO LIANG^4,*

Oncology Research, Vol.31, No.6, pp. 967-988, 2023, DOI:10.32604/or.2023.042309 - 15 September 2023

Abstract Lung adenocarcinoma (LUAD) is the most common and deadliest subtype of lung cancer. To select more targeted and effective treatments for individuals, further advances in classifying LUAD are urgently needed. The number, type, and function of T cells in the tumor microenvironment (TME) determine the progression and treatment response of LUAD. Long noncoding RNAs (lncRNAs), may regulate T cell differentiation, development, and activation. Thus, our aim was to identify T cell-related lncRNAs (T cell-Lncs) in LUAD and to investigate whether T cell-Lncs could serve as potential stratifiers and therapeutic targets. Seven T cell-Lncs were identified… More >